# Aflibercept in Polypoidal Choroidal Vasculopathy

> **NCT02120950** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 333 (actual)

## Conditions studied

- Neovascular Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- **OTHER:** Visudyne

## Key facts

- **NCT ID:** NCT02120950
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-29
- **Primary completion:** 2016-08-12
- **Final completion:** 2017-07-07
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120950, "Aflibercept in Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02120950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*